Lipocine Inc. (NASDAQ:LPCN – Get Free Report) Director John Higuchi acquired 9,037 shares of the company’s stock in a transaction dated Tuesday, September 29th. The stock was acquired at an average price of $2.15 per share, for a total transaction of $19,429.55. Following the acquisition, the director owned 225,395 shares in the company, valued at approximately $484,599.25. The trade was a 4.18% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Lipocine Price Performance
Shares of NASDAQ LPCN traded down $0.13 during midday trading on Thursday, hitting $2.07. 71,208 shares of the company’s stock were exchanged, compared to its average volume of 32,859. The firm’s fifty day simple moving average is $2.17 and its 200-day simple moving average is $2.73. The company has a market cap of $17.06 million, a PE ratio of -1.16 and a beta of 0.40. Lipocine Inc. has a twelve month low of $1.81 and a twelve month high of $12.37.
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.08. The firm had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.21 million. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%. Equities analysts anticipate that Lipocine Inc. will post -1.54 EPS for the current fiscal year.
Institutional Investors Weigh In On Lipocine
Analyst Upgrades and Downgrades
A number of research analysts recently commented on the stock. Weiss Ratings raised shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 24th. HC Wainwright reissued a “neutral” rating and issued a $4.00 price target on shares of Lipocine in a research report on Monday, September 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Lipocine in a research note on Tuesday, September 22nd. Finally, Wall Street Zen raised Lipocine from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.00.
View Our Latest Analysis on LPCN
Lipocine Company Profile
Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.
Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.
Featured Articles
- Five stocks we like better than Lipocine
- Everyone in AI Is Quietly Copying Palantir’s Playbook
- Advanced Micro Devices Is Spending $8.2 Billion to Learn What AI Needs Next
- JPMorgan Bets on Genius Sports as the Market Loses Patience
- Apple’s $5.7 Billion Patent Verdict Raises a Bigger Royalty Question
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
